AN2 Therapeutics, Inc. (ANTX)
NASDAQ: ANTX · IEX Real-Time Price · USD
2.470
+0.090 (3.78%)
Apr 19, 2024, 4:00 PM EDT - Market closed

AN2 Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Year 2023202220212020
Selling, General & Admin
14.7612.754.671.27
Research & Development
54.8729.5116.916.02
Other Operating Expenses
000.046.32
Operating Expenses
69.6442.2621.6113.61
Operating Income
-69.64-42.26-21.61-13.61
Other Expense / Income
-4.9-1.31-0.07-0
Pretax Income
-64.73-40.96-21.54-13.6
Net Income
-64.73-40.96-21.54-13.6
Preferred Dividends
01.826.520.98
Net Income Common
-64.73-42.78-28.06-14.58
Shares Outstanding (Basic)
241533
Shares Outstanding (Diluted)
241533
Shares Change
53.85%481.46%2.71%-
EPS (Basic)
-2.74-2.79-10.64-5.68
EPS (Diluted)
-2.74-2.79-10.64-5.68
Free Cash Flow
-53.29-33.46-20.48-5.36
Free Cash Flow Per Share
-2.26-2.18-7.76-2.09
EBITDA
-64.68-40.88-21.54-13.6
Depreciation & Amortization
0.050.0800
EBIT
-64.73-40.96-21.54-13.6
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).